Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression

Marine Drugs

Volumn 12, Issue 11, 2014, Pages 5396-5407

  Gilbert, Kim ^a,b   Bernier, Judith ^a,b   Godbout, Roger ^a,b   Rousseau, Guy ^a,b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Apoptosis; Depression; Limbic system; Myocardial infarction; Omega 3; Resolvin D1

Indexed keywords

OMEGA 3 FATTY ACID; RESOLVIN D1; UNCLASSIFIED DRUG; DOCOSAHEXAENOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; DEPRESSION; DRUG MECHANISM; FORCED SWIM TEST; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; ISCHEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; RAT; REPERFUSION; SOCIAL INTERACTION TEST; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MYOCARDIAL INFARCTION; NEUTROPHIL; PATHOPHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ANIMALS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; MYOCARDIAL INFARCTION; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84915748913     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12115396     Document Type: Article

References (43)

1. Meneses, R.; Almeida, M.C.; Abecasis, J.; Arroja, I.; Carvalho, A.; Aleixo, A. Depression in patients with myocardial infarction. Rev. Port. Cardiol. 2007, 26, 1143-1165.
2. Frasure-Smith, N.; Lespérance, F.; Talajic, M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993, 270, 1819-1825.
3. Bah, T.M.; Benderdour, M.; Kaloustian, S.; Karam, R.; Rousseau, G.; Godbout, R. Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behav. Brain Res. 2011, 225, 243-251.
4. Wann, B.P.; Bah, T.M.; Kaloustian, S.; Boucher, M.; Dufort, A.M.; le Marec, N.; Godbout, R.; Rousseau, G. Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: Effects of sertraline. J. Psychopharmacol. 2009, 23, 451-459.
5. Arseneault-Bréard, J.; Rondeau, I.; Gilbert, K.; Girard, S.A.; Tompkins, T.A.; Godbout, R.; Rousseau, G. Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. Br. J. Nutr. 2012, 107, 1793-1799.
6. Gilbert, K.; Arseneault-Breard, J.; Flores Monaco, F.; Beaudoin, A.; Bah, T.M.; Tompkins, T.A.; Godbout, R.; Rousseau, G. Attenuation of post-myocardial infarction depression in rats by n-3 fatty acids or probiotics starting after the onset of reperfusion. Br. J. Nutr. 2013, 109, 50-56.
7. Bah, T.M.; Kaloustian, S.; Rousseau, G.; Godbout, R. Pretreatment with pentoxifylline has antidepressant-like effects in a rat model of acute myocardial infarction. Behav. Pharmacol. 2011, 22, 779-784.
8. Rousseau, G.; Bah, T.M.; Godbout, R. Post-myocardial infarction depression. In Novel Strategies in Ischemic Heart Disease; Lakshmanadoss, U., Ed.; InTech: Rijeka, Croatia, 2012; pp. 333-362.
9. Francis, J.; Chu, Y.; Johnson, A.K.; Weiss, R.M.; Felder, R.B. Acute myocardial infarction induces hypothalamic cytokine synthesis. Am. J. Physiol. 2004, 286, H2264-H2271.
10. Kaloustian, S.; Bah, T.M.; Rondeau, I.; Mathieu, S.; Lada-Moldovan, L.; Ryvlin, P.; Godbout, R.; Rousseau, G. Tumor necrosis factor-alpha participates in apoptosis in the limbic system after myocardial infarction. Apoptosis 2009, 14, 1308-1316.
11. Van den Biggelaar, A.H.; Gussekloo, J.; de Craen, A.J.; Frolich, M.; Stek, M.L.; van der Mast, R.C.; Westendorp, R.G. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp. Gerontol. 2007, 42, 693-701.
12. Serhan, C.N. Novel eicosanoid and docosanoid mediators: Resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8, 115-121.
13. Spite, M.; Serhan, C.N. Novel lipid mediators promote resolution of acute inflammation: Impact of aspirin and statins. Cir. Res. 2010, 107, 1170-1184.
14. Serhan, C.N.; Arita, M.; Hong, S.; Gotlinger, K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004, 39, 1125-1132.
15. Serhan, C.N.; Gotlinger, K.; Hong, S.; Arita, M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: An overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 2004, 73, 155-172.
16. Serhan, C.N.; Hong, S.; Gronert, K.; Colgan, S.P.; Devchand, P.R.; Mirick, G.; Moussignac, R.L. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196, 1025-1037.
17. Ohira, T.; Arita, M.; Omori, K.; Recchiuti, A.; van Dyke, T.E.; Serhan, C.N. Resolvin e1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 2010, 285, 3451-3461.
18. Lee, H.J.; Park, M.K.; Lee, E.J.; Lee, C.H. Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. Int. J. Biochem. Cell Biol. 2013, 45, 2801-2807.
19. Serhan, C.N.; Chiang, N. Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus. Br. J. Pharmacol. 2008, 153, S200-S215.
20. Tran Quang, T.; Gosselin, A.A.; Bourque-Riel, V.; Gilbert, K.; Charron, T.; Rousseau, G. Effect of resolvin d1 on experimental myocardial infarction. Exp. Clin. Cardiol. 2014, in press.
21. Wann, B.P.; Bah, T.M.; Boucher, M.; Courtemanche, J.; le Marec, N.; Rousseau, G.; Godbout, R. Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: A possible model for human postinfarct major depression. J. Psychiatry Neurosci. 2007, 32, 11-16.
22. Simpson, P.J.; Fantone, J.C.; Mickelson, J.K.; Gallagher, K.P.; Lucchesi, B.R. Identification of a time window for therapy to reduce experimental canine myocardial injury: Suppression of neutrophil activation during 72 h of reperfusion. Circ. Res. 1988, 63, 1070-1079.
23. Sharma, H.S.; Das, D.K. Role of cytokines in myocardial ischemia and reperfusion. Mediat. Inflamm. 1997, 6, 175-183.
24. Ren, G.; Dewald, O.; Frangogiannis, N.G. Inflammatory mechanisms in myocardial infarction. Curr. Drug Targets Inflamm. Allergy 2003, 2, 242-256.
25. Nah, D.Y.; Rhee, M.Y. The inflammatory response and cardiac repair after myocardial infarction. Korean Circ. J. 2009, 39, 393-398.
26. De Lorgeril, M.; Rousseau, G.; Basmadjian, A.; St-Jean, G.; Tran, D.C.; Latour, J.G. Spacial and temporal profiles of neutrophil accumulation in the reperfused ischemic myocardium. Am. J. Cardiovasc. Pathol. 1990, 3, 143-154.
27. Mullane, K.M.; Kraemer, R.; Smith, B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods 1985, 14, 157-167.
28. Frangogiannis, N.G.; Smith, C.W.; Entman, M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002, 53, 31-47.
29. Kaloustian, S.; Wann, B.P.; Bah, T.M.; Girard, S.A.; Apostolakis, A.; Ishak, S.; Mathieu, S.; Ryvlin, P.; Godbout, R.; Rousseau, G. Apoptosis time course in the limbic system after myocardial infarction in the rat. Brain Res. 2008, 1216, 87-91.
30. Girard, S.A.; Bah, T.M.; Kaloustian, S.; Lada-Moldovan, L.; Rondeau, I.; Tompkins, T.A.; Godbout, R.; Rousseau, G. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br. J. Nutr. 2009, 102, 1420-1425.
31. Baxter, G.F.; Burley, D.S. Reperfusion and calculated risks: Pharmacological postconditioning of human myocardium. Br. J. Pharmacol. 2008, 153, 1-3.
32. Jonassen, A.K.; Sack, M.N.; Mjos, O.D.; Yellon, D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. 2001, 89, 1191-1198.
33. Boucher, M.; Pesant, S.; Falcao, S.; de Montigny, C.; Schampaert, E.; Cardinal, R.; Rousseau, G. Post-ischemic cardioprotection by A2A adenosine receptors: Dependent of phosphatidylinositol 3-kinase pathway. J. Cardiovasc. Pharmacol. 2004, 43, 416-422.
34. Bopassa, J.C.; Ferrera, R.; Gateau-Roesch, O.; Couture-Lepetit, E.; Ovize, M. Pi 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc. Res. 2006, 69, 178-185.
35. Krishnamoorthy, S.; Recchiuti, A.; Chiang, N.; Yacoubian, S.; Lee, C.H.; Yang, R.; Petasis, N.A.; Serhan, C.N. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 2010, 107, 1660-1665.
36. Bah, T.M.; Wann, B.P.; Chebli, M.; le Marec, N.; Rousseau, G.; Godbout, R. Insomnia and increased rem sleep pressure in a rat model of post myocardial infarction depression. Can. Sleep Soc. 2007, in press.
37. Bah, T.M.; Laplante, F.; Wann, B.P.; Sullivan, R.; Rousseau, G.; Godbout, R. Paradoxical sleep insomnia and decreased cholinergic neurons after myocardial infarction in rats. Sleep 2010, 33, 1703-1710.
38. Keyes, K.T.; Ye, Y.; Lin, Y.; Zhang, C.; Perez-Polo, J.R.; Gjorstrup, P.; Birnbaum, Y. Resolvin E1 protects the rat heart against reperfusion injury. Am. J. Physiol. 2010, 299, H153-H164.
39. Al-Zakwani, I.; Zubaid, M.; Al-Riyami, A.; Alanbaei, M.; Sulaiman, K.; Almahmeed, W.; Al-Motarreb, A.; Al Suwaidi, J. Primary coronary intervention versus thrombolytic therapy in myocardial infarction patients in the middle east. Int. J. Clin. Pharm. 2012, 34, 445-451.
40. Rymuza, H.; Kowalik, I.; Drzewiecki, A.; Krzyzanowski, W.; Olszewski, M.; Dabrowski, R.; Jedrzejczyk, B.; Wozniak, J.; Sosnowski, C.; Szwed, H. Successful primary coronary angioplasty improves early and long-term outcomes in st segment elevation acute coronary syndromes in patients above 80 years of age. Kardiol. Pol. 2011, 69, 346-354.
41. Westerhout, C.M.; Bonnefoy, E.; Welsh, R.C.; Steg, P.G.; Boutitie, F.; Armstrong, P.W. The influence of time from symptom onset and reperfusion strategy on 1-year survival in st-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from captim and west. Am. Heart J. 2011, 161, 283-290.
42. Gao, R.L.; Han, Y.L.; Yang, X.C.; Mao, J.M.; Fang, W.Y.; Wang, L.; Shen, W.F.; Li, Z.Q.; Jia, G.L.; Lu, S.Z.; et al. Thorombolytic therapy with rescue percutaneous coronary intervention versus primary percutaneous coronary intervention in patients with acute myocardial infarction: A multicenter randomized clinical trial. Chin. Med. J. 2010, 123, 1365-1372.
43. Borgia, F.; Goodman, S.G.; Halvorsen, S.; Cantor, W.J.; Piscione, F.; le May, M.R.; Fernandez-Aviles, F.; Sanchez, P.L.; Dimopoulos, K.; Scheller, B.; et al. Early routine percutaneous coronary intervention after fibrinolysis vs. Standard therapy in ST-segment elevation myocardial infarction: A meta-analysis. Eur. Heart J. 2010, 31, 2156-2169.